Pharmaceutical - Pharmaceutical, Exparel

Filter

Current filters:

PharmaceuticalExparel

Popular Filters

Ph III data shows Pacira’ Exparel good as femoral nerve block in knee arthroplasty

06-04-2014

US drugmaker Pacira Pharmaceuticals has released additional Phase III data supporting the efficacy and…

ExparelNeurologicalPacira PharmaceuticalsPharmaceuticalResearch

US Senator seeks answers from drugmakers on providing required discounts

27-09-2013

US Senator Charles Grassley has written to two drug companies on behalf of an Iowa hospital that is not…

CSL BehringExparelHematologyKcentraNeurologicalNorth AmericaPacira PharmaceuticalsPharmaceuticalPoliticsPricing

Exparel Ph III trial in intercostal nerve block fails to meet primary endpoint

02-08-2013

USA-based Pacira Pharmaceuticals (Nasdaq: PCRX) has reported results from its second pivotal, Phase III…

ExparelNeurologicalPacira PharmaceuticalsPharmaceuticalResearch

Skyepharma updates on Exparel, Flutiform and financial position

14-11-2011

UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Pacira and SkyePharma leap as FDA approves painkiller Exparel

02-11-2011

New Jersey, USA-based Pacira Pharmaceuticals (Nasdaq: PCRX) and UK drugmaker SkyePharma (LSE: SKP) both…

ExparelFinancialNeurologicalNorth AmericaPacira PharmaceuticalsPharmaceuticalRegulationSkyepharma

Parexel

Parexel

Back to top